Peptide-based immunotherapeutic approaches to glioma: A review

Expert Opinion on Biological Therapy

Volumn 7, Issue 5, 2007, Pages 645-649

  Yamanaka, Ryuya ^a   Itoh, Kyogo ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Glioma; Immunotherapy; Peptide vaccination

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8; HLA A24 ANTIGEN; INTERLEUKIN 13 RECEPTOR ALPHA2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; PEPTIDE VACCINE; TENASCIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE IDENTIFICATION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INJECTION SITE INFLAMMATION; METASTASIS; PROGNOSIS; REVIEW; SKIN INFLAMMATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CANCER VACCINES; GLIOMA; HUMANS; IMMUNOTHERAPY; PATIENT SELECTION; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 34248202633     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.5.645     Document Type: Review

References (48)

1. STEWART LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet (2002) 359(9311):1011-1018.
2. STUPP R, MASON WP, VAN DEN BENT MJ et al.: Radiothetapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. (2005) 352(10):987-996.
3. YAMANAK R: Novel immunotherapeutic approaches to glioma. Curr. Opin. Mol. Ther. (2006) 8(1):46-51.
4. SATOH J, LEE YB, KIM SU: T-cell costimulatory molecules B7-1 (CD80) and B7-2 (CD86) are expressed in human microglia but not in astrocytes in culture. Brain Res. (1995) 704(1):92-99.
5. CONSTAM DB, PHILIPP J, MALIPIERO UV, TEN DIJKE P, SCHACHER M, FONTANA A: Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J. Immunol. (1992) 148(5):1404-1410.
6. GABRILOVICH DI, ISHIDA T, NADAF S, OHM JE, CARBONE DP: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. (1999) 5(10):2963-2970.
7. CHEN Q, DANIEL V, MAHER DW, HERSEY P: Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int. J. Cancer (1994) 56(5):755-760.
8. YU JS, WHEELER CJ, ZELZER PM et al.: Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. (2001) 61(3):842-847. • The first dendritic cell vaccination clinical trial in patients with glioma.
9. YAJIMA N, YAMANAKA R, MINE T et al.: Immunological evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin. Cancer Res. (2005) 11(16):5900-5911. •• The first peptide vaccination clinical trial in patients with glioma.
10. KOBAYASHI K, NOGUCHI M, ITOH K, HARADA M: Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. Cancer Sci. (2003) 94:622-627.
11. NESTLE FO, ALIJAGIC S, GILLIET M et al.: Vaccination of melanoma patients with peptide- or tumor lysate pulsed dendritic cells. Nat. Med. (1998) 4(3):328-332. •• A clinical trial of peptide vaccination for patients with melanoma.
12. ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. (1998) 4(3):321-327. •• A clinical trial of peptide vaccination for patients with melanoma.
13. ROSENBERG SA, YANG JC, RESTIFO NP: Cancer immunotherapy: moving beyond current vaccines. Nat. Med. (2004) 10(9):909-915. •• A clinical trial of peptide vaccination for patients with cancer.
14. MIYAGI Y, IMAI N, SASATOMI T et al.: Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination of SART3 peptides. Clin. Cancer Res. (2001) 7(12):3950-3962.
15. NOGUCHI M, ITOH K, SUEKANE S et al.: Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate (2004) 60(1):32-45.
16. KIKUCHI T, AKASAKI Y, IRIE M, HOMMA S, ABE T, OHNO T: Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. (2001) 50(7):337-344. • The first dendritic cell vaccine clinical trial to adminster a fused dendritic-glioma cell in patients with glioma.
17. YAMANAKA R, ABE T, YAJIMA N et al.: Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial. Br. J. Cancer (2003) 89(7):1172-1179. • The first glioma clinical trial to administer a lysate-pulsed dendritic cell vaccine in patients with glioma.
18. YU JS, LIU G, YING H, YONG WH, BLACK KL, WHEELER CJ: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. (2004) 64(14):4973-4979. • A dendritic cell vaccine clinical trial to administer a lysate-pulsed dendritic cell vaccine in patients with glioma.
19. KIKUCHI T, AKASAKI Y, ABE T et al.: Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J. Immunother. (2004) 27(6):452-459. • A dendritic cell vaccine clinical trial to administer a fused dendritic-glioma cell with IL-12 in patients with glioma.
20. RUTKOWSKI S, DE VLEESCHOUWER S, KAEMPGEN E et al.: Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br. J. Cancer (2004) 91(9):1656-1662. • A clinical trial to administer a lysate-pulsed dendritic cell vaccine in patients with glioma.
21. YAMANAKA R, HOMMA J, YAJIMA N et al.: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial. Clin. Cancer Res. (2005) 11(11):4160- 4167. • A clinical trial to administer a lysate-pulsed dendritic cell vaccine in patients with glioma.
22. VAN DER BRUGGEN P, TRAVERSARI C, CHOMEZ P et al.: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254(5038):1643-1647. •• The first report of tumor antigen.
23. KAWAKAMI Y, ELIYAHU S, SAKAGUCHI K et al.: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. (1994) 180(1):347-352.
24. CHEN YT, SCANLAN MJ, SAHIN U et al.: A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA (1997) 94:1914-1918.
25. GAUGLER B, VAN DEN EYNDE B, VAN DER BRUGGEN P et al.: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. (1994) 179(3):921-930.
26. LALLIER TE: Cell lineage and cell migration in the neural crest. Ann. NY Acad. Sci. (1991) 615:158-171.
27. KURAMOTO T: Detection of MAGE-1 tumor antigen in brain tumor. Kurume Med. J. (1997) 44(1):43-51.
28. SASAKI M, NAKAHIRA K, KAWANO Y et al.: MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. Cancer Res. (2001) 61(12):4809-4814.
29. KURAPAD SN, ZHAO XG, WIKSTRAND CJ, BATRA SK, MCLENDON RE, BIGNER DD: Tumor antigens in astrocytic gliomas. Glia (1995) 15(3):244-256.
30. SAHIN U, KOSLOWSKI M, TURECI O et al.: Expression of cancer testis genes in human brain rumors. Clin. Cancer Res. (2000) 6(10):3916-3922.
31. SCARCELLA DL, CHOW CW, GONZALES MF, ECONOMOU C, BRASSEUR F, ASHLEY DM: Expression of MAGE and GAGE in high-grade brain tumors: a porential target for specific immunotherapy and diagnostic markers. Clin. Cancer Res. (1999) 5(2):335-341.
32. UEDA R, YOSHIDA K, KAWASE T, KAWAKAMI Y, TODA M: Preferential expression and frequent IgG responses of a tumor antigen, SOX5, in glioma patients. Int. J. Cancer (2007) 120:1704-1711.
33. UEDA R, IIZUKA Y, YOSHIDA K, KAWASE T, KAWAKAMI Y, TODA M: Identification of a human glioma antigen, SOX6, recognizxd by patients' sera. Oncogene (2004) 23(7):1420-1427.
34. OKANO F, STORKUS WJ, CHAMBERS WH, POLLAC IF, OKADA H: Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin. Cancer Res. (2002) 8:2851-2855.
35. HATANO M, EGUCHI J, TATSUMI T et al.: EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia (2005) 7:717-722.
36. LIU G, YU JS, ZENG G et al.: AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. J. Immunother. (2004) 27:220-226.
37. IMAIZUMI T, KURAMOTO T, MATSUNAGA K et al.: Expression of the tumor-rejection antigen SART1 in brain tumors. Int. J. Cancer (1999) 83(6):760-764.
38. MURAYAMA K, KOBAYASHI T, IMAIZUMI T et al.: Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J. Immunother. (2000) 23(5):511-518.
39. GOHARA R, IMAI N, RIKIMARU T et al.: Phase I clinical study of cyclophilin B peptide vaccine for lung cancer patients. J. Immunother. (2002) 25:439-444.
40. TSUDA N, MOCHIZUKI K, HARADA M et al.: Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J. Immunother. (2004) 27(1):60-72.
41. MINE T, SATO Y, NOGUCHI M et al.: Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing peptide-specific cellular responses. Clin. Cancer Res. (2004) 10(3):929-937.
42. ITOH K, YAMADA A: Personalized peptide vaccines: a new therapeutic modality for cancer (review). Cancer Sci. (2006) 97(10):970-976.
43. JANEWAY CA, SHLOMCHIK MJ, TRAVERS P, WALPORT M: Using the immune response to attack tumors. In: Immunobiology. 6th edn. Janeway CA, Shlomchik MJ, Travers P, Walport (Eds), Garland Science, New York, NY, USA (2004):630-642.
44. LIU G, BLACK KL, YU JS: Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert Rev. Vaccines (2006) 5:233-247.
45. LIU G, AKASAKI Y, KHONG HT et al.: Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene (2005) 24(33):5226-5234.
46. WHEELER CJ, DAS A, LIU G, YU JS, BLACK KL: Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin. Cancer Res. (2004) 10:5316-5326.
47. UEDA K, CARDARELLI C, GOTTESMAN MM, PASTAN I: Expression of full-length cDNA for the human MDR1 gene confers resistance to colchicines, doxorubicin, and vinblastine. Proc. Natl. Acad. Sci. USA (1987) 84:3004-3008.
48. GRAUER OM, NIERKENS S, BENNINK E et al.: CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int. J. Cancer (2007) (In Press).